Japan PPI inflation slips to 11-mth low in July
On August 31, 2024, Galera Therapeutics (OTC:GRTX), Inc., a pharmaceutical company, received notification from The Nasdaq Stock Market LLC (Nasdaq) regarding the delisting of its common stock. The company's securities will be delisted due to non-compliance with Nasdaq's listing rules, specifically concerning the minimum average market value, minimum bid price, and minimum market value of publicly held shares.
Trading of Galera's common stock was previously suspended on Nasdaq on June 4, 2024. Since then, the company's shares have been trading on the OTC Pink Market under the ticker symbol "GRTX." The formal delisting process began today, with the filing of Form 25 with the Securities and Exchange Commission (SEC), and it is expected to take effect ten days later.
Galera's management has not announced any intention to appeal the delisting decision. This news comes directly from a recent SEC filing by Galera Therapeutics, Inc.
In other recent news, Galera Therapeutics has announced its Board of Directors' approval of a Plan of Liquidation and Dissolution. The plan, which is subject to stockholder approval, signals the company's intent to dissolve under Delaware law. Following approval, Galera will file for dissolution and distribute the remaining cash to stockholders after settling its obligations.
The company reported a net loss of $4.1 million for the second quarter of 2024, a significant reduction from the $20.7 million loss in the same period last year.
Galera Therapeutics has also recently settled a legal dispute with two clinical research organizations, Alira Health Clinical, LLC, and IQVIA Biotech, LLC. The lawsuit, which revolved around allegations of contract breach and professional negligence, was settled for a sum of $975,000. This settlement marks the end of a significant challenge for Galera Therapeutics, allowing the company to proceed without the burden of ongoing litigation.
These are recent developments in the company's operations.
InvestingPro Insights
In light of the recent delisting of Galera Therapeutics, Inc. from Nasdaq, a closer look at real-time data from InvestingPro reveals several key financial metrics that investors may find pertinent. The company's market capitalization stands at a modest $3.4 million, reflecting the challenges it faces in the market. Galera's price-to-earnings (P/E) ratio is currently negative, both on a standard and adjusted basis for the last twelve months as of Q2 2024, indicating that the company is not generating profits relative to its share price. Additionally, the company's return on assets is deeply negative at -90.03% for the same period, underscoring the difficulties in generating positive earnings from its asset base.
InvestingPro Tips highlight several concerns for Galera, including a significant debt burden and a rapid cash burn, which are critical factors for investors to consider given the company's financial health. Analysts have revised their earnings upwards for the upcoming period, suggesting some optimism amidst the challenges. However, it's important to note that these analysts do not anticipate the company to be profitable this year. For a more comprehensive analysis, investors can explore the additional 15 InvestingPro Tips available for Galera Therapeutics at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.